Advertisement

Topics

Cognition Therapeutics Inc. Company Profile

09:11 EDT 24th September 2018 | BioPortfolio

Cognition Therapeutics, Inc. is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of diseases, and there are currently no therapeutics available to prevent or block the destructive effects of toxic oligomeric proteins. Cognition has leveraged its scientific expertise with these difficult targets to pioneer the use of proprietary assays that emphasize functional responses and proprietary medicinal chemistry that ensures novel, high quality small-molecule drug candidates for the treatment of these diseases.


News Articles [877 Associated News Articles listed on BioPortfolio]

Intense Exercise Fails to Boost Cognition in Dementia Patients

(MedPage Today) -- U.K. study shows better fitness, but not cognition

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting

Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alz...

Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer...

Menopause and Cognition: A Matter of Timing?

In a British birth cohort, later versus earlier age at menopause differentially affected subsequent cognition.

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Pittsburgh, March 14, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment o...

Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer's Disease

Pittsburgh, June 18, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today annou...

Cognition Therapeutics Presents Additional Elayta™ Clinical Results during Alzheimer's Association International Conference (AAIC) Symposium Session

Pittsburgh, July 23, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurodegenerative disorders, today an...

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease

Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheime...

PubMed Articles [782 Associated PubMed Articles listed on BioPortfolio]

Functional outcome and social cognition in bipolar disorder: Is there a connection?

Interest in social cognition in bipolar disorder (BD) has increased considerably over the past decade, with studies highlighting major impairments, especially in mental state reasoning, even during eu...

Body Composition Changes from Infancy to 4 Years and Associations with Early Childhood Cognition in Preterm and Full-Term Children.

Infants born prematurely are at risk for neurodevelopmental complications. Early growth is associated with improved later cognition. The relationship of early proportionality and body composition with...

The need for cognition and the curse of cognition.

Is the glass half empty or half full and does it even matter? Cognition, emotion, and psychopathology.

This contribution examines the outcomes of recent decades of research on the interaction between cognition and emotion and how it has informed our understanding and treatment of emotional disorders wi...

Improvements in cognition and associations with measures of aerobic fitness and muscular power following structured exercise.

Cognition, along with aerobic and muscular fitness, declines with age. Although research has shown that resistance and aerobic exercise may improve cognition, no consensus exists supporting the use of...

Clinical Trials [925 Associated Clinical Trials listed on BioPortfolio]

Effects of H1-Antagonist on Cognition

The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

Rehabilitation of Social Cognition in Subjects With Traumatic Brain Injury

In the present study we aim to analyze the performance in a battery of social cognition tests of subjects with traumatic brain injury. On the other hand, the effectiveness of a computeriz...

Efficacy of Social Cognition Training in Schizophrenia

The term social cognition refers to how social information is processed. Individuals with schizophrenia and schizoaffective disorder have been shown to have significant deficits in social ...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Companies [1274 Associated Companies listed on BioPortfolio]

Cognition Therapeutics Inc.

Cognition Therapeutics, Inc. is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disea...

Cambridge Cognition Ltd

Cambridge Cognition Ltd specialises in computerised cognitive testing. Based in Cambridge, England, the company supplies products and services based on CANTAB®, the Cambridge Neuropsychological Test ...

MPI Cognition

Neurodyn Cognition Inc.

NCI is a private Canadian biotech company developing Memogain, a patented prodrug of an approved treatment for Alzheimer’s disease, galantamine (Reminyl®). Memogain’s...

Savonix

Savonix delivers the world's first fully mobile, evidence-based assessment of cognitive function. Available on Android and iOS for phone and tablet, Savonix Mobile is an accurate,...

More Information about "Cognition Therapeutics Inc." on BioPortfolio

We have published hundreds of Cognition Therapeutics Inc. news stories on BioPortfolio along with dozens of Cognition Therapeutics Inc. Clinical Trials and PubMed Articles about Cognition Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cognition Therapeutics Inc. Companies in our database. You can also find out about relevant Cognition Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record